Back to top

October 2020

  /    /  October

The LACOG Genitourinary Group, the arm of LACOG that focuses on genitourinary cancer, is holding the GU Review 2020 online between October 29th to 31st with many extra features! As well as the free 3 day program online, there will be pre-conference courses, educational activities, doctors discussing the pros and cons of various treatments and multidisciplinary classes available for medical, nursing, physiotherapy, pharmacy and nutritional practitioners. ⠀ The event will bringing together participants from all over the world and there will be simultaneous translation into English and Spanish. Healthcare professionals will also be able to take part in LACOG’s Second GU Multi-profession Symposium. ⠀⠀ Sign up here:

The same way it happens in developed countries, non-small cell lung cancer (NSCLC) is generally diagnosed in its advanced stages and has poor survival rates in Brazil. Overall, approximately 70% of patients present with locally advanced or metastatic disease (stages III and IV, respectively) at diagnosis.1 In order to collect data on clinical characteristics, treatment patterns and outcomes of patients with stage III NSCLC in Brazil, Dr. Vladmir Cláudio Cordeiro de Lima started the observational study Retrospective epidemiological study of Locally Advanced Non-Small Cell Lung Cancer (LACOG 0118 – RELANCE). He has worked as the principal investigator of the study ever since. Dr. Cordeiro de Lima is a clinical oncologist at the Department of Clinical Oncology at the AC Camargo Cancer Center. He also works as a permanent advisor of the Postgraduate Course in Sciences focused on the Oncology area at the Antônio Prudente Foundation, and as an investigator at the Translational Immuno-oncology Laboratory (CIPE) at the Antônio Prudente Foundation. The study aims to describe the outcomes of 400 patients with locally advanced NSCLC (stage III). The study is supported by LACOG and, according to Dr. Cordeiro de Lima, this support is extremely important because cooperative groups help to bring together and

In the last decades, clinical research has established the main source of knowledge in the field of Oncology. The development of drugs that improve quality of life and patient survival through clinical research is undeniably important. However, Latin American countries play a small role in this scenario since most clinical studies are developed in European and North American centres. For that reason, reinforcing the importance of Latin-American countries participation and promotion of clinical trials is imperative. Being more engaged in research, Latin America would not only contribute with the scientific community, but also allow patients to have access to new treatment options. A close relationship among the investigator, the research centre and the Research Organisation is the keystone of research development in Latin America. Since 2009, LACOG has been an important Research Organisation in Latin America which provides investigators with the necessary support throughout the whole research process. LACOG is an independent multinational cooperative group that plays a central role in the development and conduction of clinical trials and academic studies. Additionally, LACOG works in cooperation with other international academic institutions, biotechnological and pharmaceutical centres and industries in order to promote and conduct clinical trials. The active participation of investigators is crucial to the development